A Phase III Study on the Safety, Pharmacokinetics and Ef

Project: Research project

Description

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor Vlla (Recombinant) in Congenital Hemophilia A or B Patients with Inhibitors to Factor VIII or IX
StatusFinished
Effective start/end date6/1/145/31/18

Funding

  • REVO BIOLOGICS, INC.

Fingerprint

Hemophilia B
Factor IX
Blood Coagulation Factors
Factor VIII
Hemophilia A
Pharmacokinetics
Safety